Observed Signal · Sep 9, 2026 · Funding · Source: Tech.eu (European Tech & Deals) · Impact: 1/5 · Sentiment: Positive
Anemo Labs Raises £700K for AI E-Nose
London-based deeptech startup Anemo Labs has raised £700,000 in pre-seed funding to develop an electronic nose (e-nose) that combines sensor hardware with AI to detect volatile organic compounds (VOCs). The round was led by Zinc and SFC Capital with support from Innovate UK. Founded in 2025 by Koye Sodipo, the company initially targets healthcare applications, analyzing VOCs from urine for non-invasive disease screening. Anemo's in-house sampling platform can collect and label up to 5,000 smells daily, and early tests using the Sniffin' Sticks protocol achieved 84.15% accuracy across 12 scent categories. The funding will advance sensor chemistry, expand data collection, and support clinical validation.
Early-stage funding in a niche deeptech sector (e-nose for healthcare) with limited direct immediate impact on the AdTech/MarTech industry.
Track SFC Capital Signals & Market Shifts in Real-Time
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Anemo Labs raised £700,000 in pre-seed funding.
- The funding round was led by Zinc and SFC Capital, with support from Innovate UK.
- Anemo Labs is developing an electronic nose combining sensor hardware and AI to detect VOCs.
- The company's technology aims for non-invasive disease screening via urine analysis.
- Early tests showed 84.15% accuracy in classifying 12 scent categories using Sniffin' Sticks protocol.
Connected Companies & Entities
“The round was led by Zinc and SFC Capital, with additional support from Innovate UK.”
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
AcouBatt Raises £1.1M for Battery Diagnostics Tech
London-based deeptech startup AcouBatt has raised £1.1 million in pre-seed funding to develop its battery diagnostics technology, which uses acoustic emission sensing and AI to monitor lithium-ion battery cell manufacturing. The round was led by Creator Fund with participation from Ada Ventures. Founded in 2025 by Dr Arthur Fordham and Chris Haoxin Xu, the company spun out of UCL Ventures. Its technology, based on PhD research, aims to reduce formation time by up to 30% and detect faults early. Sensors are deployed at the UK Battery Industrialisation Centre for benchmarking. Funds will expand the team and advance industrial pilots.
XRlabs Raises €7.48M for AI Surgical Intelligence
London-based XRlabs, a Surgical Intelligence company founded by neurosurgeon Dr. Ali Haddad, has raised €7.48 million ($8.4 million) in Seed funding. The round was led by Playground Global (Palo Alto), with participation from London-based HealthTech investor Eka Ventures. The company develops modular, device-agnostic software that uses computer vision and deep learning to transform live surgical video, navigation telemetry, and pre-operative imaging into a real-time, anatomy-aware view. Its platform has been deployed in over 100 surgical cases across three continents. The funding will support engineering and clinical team expansion, regulatory advancement in the UK, EU, and US, and the extension of clinical evidence. XRlabs also announced Omar Ishrak, former CEO of Medtronic, as Chair of its Board. The company has been awarded compute allocation on the UK AI Research Resource (AIRR).
Biomatter Raises $18M for AI Enzyme Design
Biomatter, a Vilnius-based enzyme design company, has raised $18 million (€16.2 million) in an oversubscribed Series A round led by Astanor, with participation from existing investors UVC Partners, Inventure, and Metaplanet. Using an AI-driven platform, the company designs custom enzymes from first principles, reducing development time from months or years to weeks. Biomatter has delivered over 50 custom enzymes to more than 25 enterprise clients, including AstraZeneca, BASF, Sanofi, Thermo Fisher Scientific, and Kirin Holdings. Its enzymes are used in commercial products, such as for mRNA research, developed with Thermo Fisher Scientific. The new funding will support a 2,000-square-metre design-and-testing facility in Vilnius, scheduled to open in 2027, and expand commercial operations in the United States.
Receive all future signals for SFC Capital & competitors in your briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.